4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

The overall lifetime risk of heart failure (HF) is similar between men and women, however,
there are marked sex differences in the landscape of this condition that are both important …

Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high
mortality, developing as a continuum, and progressing from the initial insult (underlying …

Acute heart failure (AHF) is a syndrome defined as the new onset (de novo heart failure
(HF)) or worsening (acutely decompensated heart failure (ADHF)) of symptoms and signs of …

Background: Cardiomyopathies are a heterogeneous group of pathologies characterized by
structural and functional alterations of the heart. Aims: The purpose of this narrative review is …

Abstract Cardiovascular disease complicates 1–4% of pregnancies—with a higher
prevalence when including hypertensive disorders—and is the leading cause of maternal …